Join us for the MGB Gene and Cell Therapy Research Symposium, 2023, hosted by the Gene and Cell Therapy Institute and in collaboration with the Mass General Research Institute and Brigham Research Institute where groundbreaking discoveries and advancements in gene and cell therapy will be shared and discussed. This in-person event will take place on Thursday, November 16, 2023 at 399 Revolution Drive, Somerville, MA 02145.

At the symposium, esteemed researchers, scientists, and industry professionals from around the world will come together to exchange knowledge, present their latest findings, and explore the potential of gene and cell therapy in revolutionizing healthcare.

With an informal and collaborative atmosphere, this symposium offers a unique opportunity to network, engage in stimulating discussions, and foster collaborations with experts in the field. Attendees will have the chance to learn about cutting-edge research, innovative technologies, and emerging trends in gene and cell therapy.

Don’t miss out on this exciting event that will shape the future of gene and cell therapy. Join us at the MGB Gene and Cell Therapy Research Symposium, 2023, and be part of the revolution in gene and cell therapy.

Keynote Speaker
R. Jude Samulksi, PhD
The MGB Gene and Cell Therapy Institute is pleased to announce that President, Chief Scientific Officer, and Co-Founder of AskBio, R. Jude Samulksi, PhD will be one of the keynote speakers at the MGB Gene and Cell Therapy Research Symposium.

Dr. Samulski is a world-renowned figure in gene therapy. He earned his Ph.D. in medical microbiology and immunology from the University of Florida, pioneering the use of AAV2 as a viral vector during his graduate years. This groundbreaking work led to the first FDA-approved gene therapy for Leber Congenital Amaurosis. Following post-doctoral training at Princeton, he continued his impactful research at the University of Pittsburgh, achieving the first use of AAV for gene delivery to the Central Nervous System, ultimately contributing to treatments for Canavan’s disease.

In 1993, he embarked on a transformative journey at the University of North Carolina, where he founded and led the UNC Gene Therapy Center for 25 years. During this time, he made significant contributions, including the development of self-complementary AAV vectors and chimeric AAV capsids for gene therapy.

Dr. Samulski has dedicated four decades to AAV research, with notable achievements in the treatment of rare disorders. He co-founded Bamboo Therapeutics, later acquired by Pfizer, where he played a pivotal role in advancing gene therapy for Duchenne muscular dystrophy. He also co-founded AskBio which is advancing gene therapy on all fronts for millions of patients. Dr. Samulski’s impact extends beyond the lab, as he has advised the FDA and received recognition from the American Society of Cell and Gene Therapy. His mission continues at the Columbus Children’s Foundation, focusing on AAV gene therapies for ultra-rare disorders. He holds numerous patents and has published over 350 articles in the field. Currently, he serves as a professor at UNC and remains at the forefront of gene therapy advancements.

Register now to attend the symposium and learn more from Dr. Samulski’s keynote address. We look forward to seeing you there!

Keynote Speaker
Siddhartha Mukherjee, MD, DPhil
The MGB Gene and Cell Therapy Institute is pleased to announce that oncologist, physician, and acclaimed author Siddhartha Mukherjee, M.D., Ph.D will be the keynote speaker at the MGB Gene and Cell Therapy Research Symposium.

Trained at the Dana-Farber Cancer Institute of Harvard Medical School and a former staff member at Massachusetts General Hospital, Dr. Mukherjee holds a DPhil in immunology from Oxford as a Rhodes Scholar and an MD from Harvard Medical School. His literary contributions, including “The Emperor of All Maladies: A Biography of Cancer” (Pulitzer Prize winner) and “The Gene: An Intimate History,” have earned international recognition.

Currently a professor of medicine at Columbia University and a dedicated cancer physician, Dr. Mukherjee also chairs the Scientific Advisory Board for Vor Biopharma, with the goals of his laboratory focusing in malignant and premalignant blood diseases, and a goal of developing novel therapeutic strategies.

Register now to attend the symposium and learn more from Dr. Mukherjee’s keynote address. There will also be a book signing event at the end of the symposium led by Dr. Mukherjee of his newest piece of literature, “The Song of the Cell: An Exploration of Medicine and the New Human.” Availability is based on a first come first served basis. We look forward to seeing you there!